Use of Biomarkers to Predict CAR-T Outcomes | Darren Pan, MD | ASH 2023

Addressing Racial and Ethnic Disparities in AML Clinical Trials | Andrew Hantel, MD | ASH 2023

Study on Minimizing Exclusion for AML Patients in Clinical Trials | Andrew Hantel, MD | ASH 2023

Loncastuximab for High-Risk Relapsed/Refractory FL | Juan Pablo Alderuccio, MD | ASH 2023

Results from Venetoclax Added to CLAD Combo for Older Patients With AML | Tapan Kadia, MD | ASH 2023

Costs & Financial Hardship Among BMT CTN 1102 Patients MDS | Christopher Su, MD | ASH 2023

Trial of an Education Video for CAR T-cell Therapy Recipients

Costs of Venetoclax-Obinutuzumab vs. BTKi in CLL | Scott Huntington, MD, MPH, MSc | ASH 2023

Moving to a Fully Oral Drug Combination for Older/Frail AML Patients | Tapan Kadia, MD | ASH 2023

Exploring Drug Options for MDS Patients with XPO1 Inhibitors | Justin Taylor, MD & Sana Chaudhry, BS | ASH 2023

Extending AML Remissions with Hypomethylating Agents and Venetoclax | Tapan Kadia, MD | ASH 2023

Fighting DLBCL by Attacking the Microenviroment | Leandro Cerchietti, MD | ASH 2023

Older Patients Experience Improved QOL with NHL Treatments

Effects of Stem Cell Infusion with BCMA CAR-T | Meera Mohan, MD | ASH 2023

Real World Teclistamab Results for Relapsed Refractory Myeloma Patients | Meera Mohan, MD | ASH 2023

Moving Towards Immunotherapy for Newly Diagnosed DLBCL Patients | Paolo Strati, MD | ASH 2023

Updates to Management of CAR-T and Teclistamab for Myeloma Patients | Radhika Bansal, MD | ASH 2023

iStopMM Trial in Iceland #myeloma | Jón Þórir Óskarsson, MSc | ASH 2023

Impact of Financial Toxicity and Time Toxicity in Myeloma QOL | Rahul Banerjee, MD, FACP | ASH 2023

Real-World Bortezomib Patterns in Newly Diagnosed Myeloma | Gurbakhash Kaur, MD, MA | ASH 2023